OVERVIEW

9th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship is organized by Cedars-Sinai Medical Center. This online CME course will be held on Nov 13, 2020.

Modules Release/Expiration Dates:
Release Date: November 1, 2020
Expiration Date: October 31, 2021
Live Virtual Activity: November 13, 2020

Accreditation:
Credit Designation Statement:
Cedars-Sinai Medical Center assigns this blended on-demand and live virtual activity for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians will be able to earn the credit commensurate based on the extent of their participation in the activity.

Credits:
AMA PRA Category 1 Credit(s)™ (MD, DO) (9.00 hours), Non-Physician Attendance (RN, NP, PA, and Others) (9.00 hours)

Course Overview:
This extensive educational activity will cover a Live Virtual Activity on November 13, 2020, and a series of 15 on-demand modules. The CME webinar will accord guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants, and pharmacists, with the most prevailing data available about the newest agents in oncology and explaining the newest research to their patients. The content will address drug and treatment strategies with an emphasis on myeloma, gynecological malignancies, hematologic malignancies, sarcoma, bladder cancer, and GI malignancies. This CME activity highlights an extensive survey of novel drugs recognized in 2020 along with their mechanism of action, next-generation CAR cell therapies, and a keynote lecture describing advances in immunotherapy. Next-generation studies will also be addressed, and the activity will allow the participants a module devised to present insight into the latest advances in lung cancer treatment, including the integration of new molecularly-targeted therapies and immunotherapy.

Course Objectives:
• Estimate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of cancer patients
• Generate personalized treatment plans for patients based upon an evaluation of efficacy and safety of current and newly approved agents and therapeutic options
• Combine the appropriate strategies into clinical practice to optimize the management of patients with gynecologic malignancies to improve patient outcomes
• Employ AJCC or other relevant staging in clinical practice, including appropriate prognostic indicators and evidence-based national guidelines for treatment planning
• Anticipate the requirements and issues of cancer survivors and explain an individualized wellness plan in partnership with cancer survivors, their families, and the healthcare team